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Genetic polymorphism of VEGF: Impact on longitudinal
change of peritoneal transport and survival of peritoneal dialy-
sis patients.
Background. Vascular endothelial growth factor (VEGF)
plays a pivotal role in the peritoneal angiogenesis and hyper-
permeability in patients on peritoneal dialysis. We hypothesis
that VEGF genetic polymorphism may affect the longitudinal
change of peritoneal transport and clinical outcome of peri-
toneal dialysis patients.
Methods. We studied 135 consecutive new peritoneal dialysis
patients. VEGF genetic polymorphism at –1154 and –2578 po-
sitions were determined by polymerase chain reaction (PCR)
methodologies. Standard peritoneal test and dialysis adequacy
and transport test (DATT) were performed at the initiation of
peritoneal dialysis. After 12 months, DATT was repeated in 83
patients. In 35 patients, VEGF production in vivo was deter-
mined by its levels in serum and peritoneal dialysis effluent,
and mRNA expression in peritoneal dialysis effluent. Patients
were followed for 19.4 ± 8.5 months for survival study.
Results. There was no relation between VEGF genotype and
baseline peritoneal transport group. The changes in 24-hour
dialysate-to-plasma (D/P) creatinine after 12 months were 0.028
± 0.159, -0.013 ± 0.137, and 0.141 ± 0.231 for CC, CA, and
AA genotype at –2578 position, respectively [one-way analy-
sis of variance (ANOVA), P = 0.028]. The AA genotype had
significantly higher increase in 24-hour D/P creatinine than the
other genotypes. Similar results were found with the genotype at
−1154 position, which had marked linkage disequilibrium with
the genotype at –2578 position. Actuarial patient survival was
90.3% and 74.9% at 24 months for CC and CA/AA genotypes
at –2578 position, respectively (P = 0.036). After correcting for
confounding covariates, the adjusted hazard ratio of death was
3.04 (95% CI, 1.10 to 8.36) for the CA/AA group as compared
to CC group. Although baseline serum VEGF level was higher
in patients with CC genotype than those with CA/AA genotype
at –2578 position (541.5 ± 322.8 pg/mL vs. 298.8 ± 209.4 pg/mL,
P = 0.012), VEGF mRNA expression in peritoneal dialysis
effluent was significantly lower in patients with CC genotype
(1.82 ± 2.77 vs 4.48 ± 3.28, P = 0.021). VEGF protein level in
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peritoneal dialysis effluent was also marginally lower in patients
with CC genotype, although the difference was not significant.
Genotype at –1154 position was not associated with VEGF pro-
duction in vivo or patient survival.
Conclusion. We conclude that in peritoneal dialysis patients,
the AA genotype of VEGF promoter at –2578 position was as-
sociated with progressive increase in peritoneal transport. The
CA/AA genotype at –2578 position was also associated with
an excess mortality. Our finding also suggests that systemic
and local peritoneal VEGF production may be differentially
regulated.
Vascular endothelial growth factor (VEGF) is a ma-
jor regulator of normal and abnormal angiogenesis [1].
Evidence suggests that VEGF plays an important role
in peritoneal transport. VEGF is produced locally in hu-
man peritoneal membrane, and VEGF level in peritoneal
dialysis effluent correlated with peritoneal permeability
in vivo [2]. There is spontaneous production of VEGF
by cultured peritoneal mesothelial cells [3], and recent
studies demonstrated an up-regulation of VEGF in the
peritoneum of patients on long-term peritoneal dialysis
[4].
The gene encoding VEGF is located on chromosome
6 and comprises a 14 kb coding region with 8 exons
and 7 introns [5]. Five polymorphisms, which may have
functional significance, have been identified in the 5′-
promotor region of the VEGF gene by single-stranded
conformational polymorphism analysis and sequencing
[6]. Genetic polymorphism of the VEGF promoter has
been found to affect the production of VEGF pro-
tein by lipopolysaccharide-stimulated peripheral blood
mononuclear cell [7, 8]. In addition, polymorphism of
the VEGF gene 5′-untranslated region is a genetic risk
factor for diabetic retinopathy [9], a condition charac-
terized by abnormal new vessel formation secondary to
high glucose level [10]. Since peritoneal microvascular
dysfunction secondary to high glucose exposure may also
be related to the up-regulation of VEGF [11], we hypoth-
esis that VEGF promoter polymorphism may contribute
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to the longitudinal change of peritoneal transport in peri-
toneal dialysis patients.
METHODS
Study arrangement
From October 1999 to September 2001, we studied
135 consecutive patients started on continuous ambu-
latory peritoneal dialysis. Baseline data including age,
gender, underlying renal disease, dialysis regimen, hep-
atitis B status, and presence of diabetes mellitus were
obtained. Standard peritoneal permeability test [12] was
performed within 8 weeks after the commencement of
peritoneal dialysis. Dialysis adequacy and transport test
(DATT) [13] was performed on either the day before or
after the peritoneal equilibration test; and then DATT
was repeated approximately 12 months after the patient
was on peritoneal dialysis to study the change in peri-
toneal transport status [14]. Both the peritoneal equili-
bration test and DATT were performed when the patient
was clinically euvolemic and at least 1 month after res-
olution of any acute medical problem. All patients were
followed for at least 12 months for survival study. Actuar-
ial patient survival was censored at the time of transfer to
long-term hemodialysis or transplantation. Patients who
remained alive and on peritoneal dialysis on October 1,
2002, were administratively censored for analysis of ac-
tuarial patient survival.
Study of peritoneal transport
Standard peritoneal equilibration test was performed
by the method of Twardowski et al [12]. Briefly, a 4-hour
dwell study was carried out with 2 L of dextrose 2.5%
dialysis fluid (Dianeal) (Baxter-Travenol, Deerfield, IL,
USA). Dialysate creatinine and glucose levels at 0, 2,
and 4 hours, plasma creatinine, and glucose levels at 2
hour were measured. Serum albumin and C-reactive pro-
tein (CRP) levels were also measured at the same time.
CRP was measured by the Tina-quant CRP (Latex) ultra-
sensitive assay (Roche Diagnostics GmbH, Mannheim,
Germany). Drainage and ultrafiltration volumes at 4 hour
are documented. Creatinine concentration in dialysate is
corrected for glucose interference according to a formula
provided by our laboratory [15]. Dialysate-to-plasma ra-
tios of creatinine (D/P) at 0, 2, and 4 hours are calculated
after correction of glucose interference. The results were
plotted on a peritoneal equilibration test graph. Patients
were classified into high, high-average, low-average, and
low transporters as described by Twardowski et al [12].
Mass transfer area coefficients of creatinine (MTAC) nor-
malized for body surface area (BSA) was calculated by
the formula described by Krediet et al [16]. BSA is deter-
mined from body weight and height by nomogram [17].
Dialysis adequacy and transport test
DATT was performed either the day before or after the
peritoneal equilibration test and then repeated approxi-
mately 12 months after the patient was on peritoneal dial-
ysis. The method of DATT has been described previously
[13, 14, 18]. Briefly, all patients were instructed to bring
all the bags of spent dialysis effluent during the previous
24 hours without changing their habitual prescription of
dialysis glucose concentration. We did not standardize
the dwell times and the patients were allowed to perform
their exchanges as usual. The blood sample was drawn
in the morning of the day following the collection when
the bags were delivered. Dialysis effluent of all the bags
was mixed in a container, the volume was measured and
registered, and then a 10 mL aliquot was obtained for
biochemical analysis. Residual glomerular filtration rate
(GFR) was also measured by 24-hour urine collection at
0 and 12 months during DATT. Residual GFR was calcu-
lated as average of 24-hour urinary urea and creatinine
clearance as described [19].
Glucose exposure
Glucose exposure was expression as the total annual
exposure to glucose calculated from the dialysis regimen
reported every 6 months as described by Davies et al [20].
The product of the volume and the glucose concentration
for each exchange was calculated. For example, for an
individual who was using 4 × 2 L exchanges (2 × 1.36%,
1 × 2.27%, and 1 × 3.86%), there would be 54.4 + 45.4 +
77.2 = 176.8 g of glucose per day. This is equivalent to
64,532 g of glucose per year.
Identification of VEGF genotypes
Amplification refractory mutation system by poly-
merase chain reaction (PCR) methodologies were de-
veloped for the single nucleotide substitutions at the
positions –1154 (203 bp), and –2578 (239 bp) in the
VEGF gene as described previously [6, 8, 21]. Briefly,
blood leukocyte DNA was amplified in a 10 lL reaction
comprising PCR master mix (ABgene) (ABgene Ltd.,
Epsom, UK), VEGF primers (5 lmol/L) [6], human
growth hormone primers (1 lmol/L; internal control,
429 bp), and 25 to 100 ng of DNA. Amplifications were
performed by using annealing temperatures of 65◦C
(10 cycles) and 59◦C (20 cycles). Amplified products were
resolved in 2% agarose gels.
Study of VEGF production in vivo
Baseline VEGF level in serum and peritoneal dialysis
effluent at 4 hours of peritoneal equilibration test was de-
termined in 35 patients by using human VEGF enzyme-
linked immunosorbent assay (ELISA) kit (Quantikine)
(R&D Systems, Abingdon, UK). After collection of the
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specimens, cell-free peritoneal dialysis effluent samples
and serum were stored at −70◦C until analysis. The assay
was performed according to the manufacturer’s instruc-
tion. The detection limit of the ELISA kit was 9 pg/mL.
All tests were performed in duplicates and were assayed
at the same time to avoid interbatch variation. Intra-assay
coefficient of variation was less than 8%.
To further examine the intra-peritoneal VEGF gene
expression, the dialysis effluent drained after baseline
peritoneal equilibration test (approximately 2 L) was
used for RNA extraction in the same 35 patients. Our
methods of RNA extraction has been described previ-
ously [22]. Briefly, the complete drainage of peritoneal
dialysis effluent at 4 hours of peritoneal equilibration
test was centrifuged at 3000g for 30 minutes at 4◦C. To-
tal RNA was extracted from the centrifuge sediment by
the RNeasy Mini Kit (Qiagen, Inc., Mississauga, Ontario,
Canada). All specimens were pretreated with deoxyri-
bonuclease, followed by reverse transcription (RT) and
real time quantitative PCR (RT-QPCR). Briefly, around
0.5 lg of RNA was reverse transcribed to complemen-
tary DNA. RT-QPCR was performed by ABI Prism 7700
Sequence Detector System (Applied Biosystems, Foster
City, CA, USA). TaqMan primers and probe was pur-
chased from Applied Biosystems. Forward primer was 5′-
TAC CTC CAC CAT GCC AAG TG-3′; reverse primer
was 5′-CTC CTG GAA GAT GTC CAC CA-3′; probe
sequence was 5′-TCA GCG CAG CTA CTG CCA TCC
AAT-3′. VEGF mRNA expression was calculated by
using the change in threshold cycle (Ct) proce-
dure according to manufacturer’s instruction, with
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
used as housekeeping gene for normalization among sam-
ples. The results were analyzed by Sequence Detection
Software, version 1.7 (Applied Biosystems).
Statistical analysis
Statistical analysis was performed by SYSTAT 7.0 for
Windows software (SPSS Inc., Chicago, IL, USA). Re-
sults were expressed as mean ± SD unless otherwise
specified. A P value of less than 0.05 was considered sig-
nificant. All probabilities were two-tailed. Comparisons
between groups were performed by chi-square test, Stu-
dent t test or one-way analysis of variance (ANOVA) as
appropriate. The effect of VEGF promoter genotype on
the longitudinal change of peritoneal transport charac-
teristics was analyzed by ANOVA for repeated measures,
with VEGF genotype as the independent grouping factor.
Since CC genotype at the –2578 position was considered
the “wild-type” and the number of patients that had AA
genotype was few, patients were categorized into either
CC or CA/AA group for analysis of survival data and
VEGF production in vivo.
Kaplan-Meier analysis and the log rank test were used
to explore the effect of VEGF genotype on actuarial
Table 1. Demographic and clinical information
No. of patients 135
Gender male:female 66:69
Age years 57.4 ± 15.2
Body height m 1.59 ± 0.10
Body weight kg 57.8 ± 11.8
Renal diagnosis number of cases
Glomerulonephritis 41 (30.4%)
Diabetic nephropathy 54 (40.0%)
Polycystic kidney 4 (3.0%)
Hypertensive nephrosclerosis 6 (4.4%)
Obstructive uropathy 6 (4.4%)
Others/unknown 24 (17.8%)
Comorbid conditions number of cases
Diabetes mellitus 61 (45.2%)
Cardiovascular disease 28 (20.7%)
Hepatitis B surface antigen carrier 12 (8.9%)
survival. To further analyze the effect of VEGF poly-
morphism at –2578 position on survival after excluding
potential confounding variables, a multivariable Cox
model was constructed. Because 20 patients died during
the study period, only two independent variables could
be included in the Cox model without overfitting. As a
result, a propensity score to combine all the potential con-
founders was used for the Cox model analysis in order to
adjust for the effect of other confounding variables when
estimating the effect of VEGF polymorphism on survival
[23]. Similar to that described in our previous study [24],
the propensity score was found by predicting genotype
group (CC as opposed to CA/AA) from the potential con-
founding variables, which included patient’s gender, age,
diabetic status, preexisting cardiovascular disease, body
weight and height, net ultrafiltration and 4-hour D/P crea-
tinine during peritoneal equilibration test, baseline serum
albumin, total Kt/V, residual GFR, normalized protein
nitrogen appearance, and percentage of lean body mass,
by a logistic regression analysis. These variables were se-
lected because their values were appreciable differences
between the genotype groups (although the values might
not be statistically significant [24]), or previous studies
found that the parameter had significant impact on pa-
tient survival [25, 26]. In either case, the parameter was
considered potentially confounding and needed to be ad-
justed for while estimating the effect of VEGF genotype.
Each patient in the study then had a calculated propen-
sity score, which was the estimated probability (as deter-
mined by that patient’s covariate values) of having CC
versus CA/AA genotype. This propensity score was then
the single summarized confounding covariate that was
forced into the multivariable Cox survival model.
RESULTS
We studied 135 consecutive new peritoneal dialysis pa-
tients. The demographic and baseline clinical informa-
tion are summarized in Table 1. The residual GFR of our
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Table 2. Vascular endothelial growth factor (VEGF) genotype and
peritoneal transport group at baseline
–1154 position –2578 position
Transporter GG GA AA CC CA AA
Low 8 6 0 7 6 1
Low-average 20 14 4 17 18 3
High-average 22 12 2 20 14 2
High 23 22 2 20 24 3
patients were 3.66 ± 2.35 mL/min/1.73 m2. The average
4-hour D/P by peritoneal equilibration test was 0.608 ±
0.140; the average MTAC creatinine was 9.12 ± 4.80
mL/min. The average 24-hour D/P creatinine by DATT
was 0.755 ± 0.127. From the standard peritoneal equili-
bration test, there were 36 low transporters (26.7%), 47
low-average transporters (34.8%), 38 high-average trans-
porters (28.1%), and 14 high transporters (10.4%). Of the
135 patients, 73 (54.1%) had GG, 54 (40.0%) had GA,
and eight (5.9%) had AA genotype at –1154 position.
At the –2578 position, 64 patients (47.4%) had CC, 62
(45.9%) had CA, and nine (6.7%) had AA genotype. The
polymorphisms at –1154 and –2578 positions had marked
linkage disequilibrium (chi-square = 173.9, P < 0.0001).
VEGF genotype and baseline peritoneal transport
The distribution of VEGF genotype and peritoneal
transport group are summarized in Table 2. There was no
relation between VEGF genotype and peritoneal trans-
port group (chi-square test, P = 0.67 and 0.95 for –1154
and –2578 positions, respectively). Further analysis did
not show any difference in D/P at 4 hours or MTAC of cre-
atinine between the genotype groups. For the polymor-
phism at –1154 position, the D/P at 4 hours were 0.597 ±
0.148 versus 0.617 ± 0.127 for the GG and GA/AA
groups, respectively (Student t test, P = 0.41); the MTAC
of creatinine were 8.70 ± 4.25 mL/min versus 9.43 ±
5.21 mL/min for the GG and GA/AA groups respectively
(P = 0.38). For the polymorphism at –2578 position, the
D/P at 4 hours were 0.596 ± 0.153 versus 0.619 ± 0.128 for
the CC and CA/AA groups, respectively (Student t test,
P = 0.36); the MTAC of creatinine were 8.67 ± 4.35
mL/min versus 9.53 ± 5.16 mL/min for the CC and
CA/AA groups respectively (P = 0.30).
VEGF genotype and longitudinal change
of peritoneal transport
All patients received three 2 L exchanges a day at 0
month. There was a significant correlation between D/P at
4 hours by standard peritoneal equilibration test and 24-
hour D/P creatinine by DATT at 0 month (r = 0.695, P <
0.001). After 12 months of follow-up, 83 patients (61.5%)
remained on three exchanges a day without any change
in the tonicity of the solution used, and serial DATT was
performed. The 24-hour D/P creatinine by DATT at 0 and
12 months were summarized in Figure 1. ANOVA with
repeated measurements showed that there was signifi-
cant interaction between the VEGF genotype at –1154
position with time (P = 0.017), as well at genotype at
−2578 position with time (P = 0.028), indicating signif-
icant effect of the two genotypes on the longitudinal
change in 24-hour D/P creatinine. The changes in 24-
hour D/P creatinine over 12 months were 0.029 ± 0.171,
−0.026 ± 0.104, and 0.161 ± 0.223 for GG, GA, and
AA genotype at –1154 position, respectively (one-way
ANOVA, P = 0.017). Glucose exposure over 12 months
were 19.8 ± 3.4 kg, 19.1 ± 3.1 kg, and 18.7 ± 3.5 kg for the
three groups, respectively (one-way ANOVA, P = 0.4).
Post hoc analysis by the Bonferroni method showed that
AA genotype had significantly higher increase in 24-hour
D/P creatinine than the other groups (P = 0.015).
Similarly, the changes in 24-hour D/P creatinine over 12
months were 0.028 ± 0.159, −0.013 ± 0.137, and 0.141 ±
0.231 for CC, CA, and AA genotype at –2578 position,
respectively (one-way ANOVA, P = 0.028). Glucose ex-
posure over 12 months were 19.8 ± 3.5 kg, 19.1 ± 3.1
kg, and 19.2 ± 3.2 kg for the three groups, respectively
(one-way ANOVA, P = 0.5). Post hoc analysis showed
that AA genotype had significantly higher increase in 24-
hour D/P creatinine than the other groups (P = 0.03). The
effect of VEGF genotype on the change in 24-hour D/P
creatinine remained similar when patients with and with-
out peritonitis episodes were analyzed separately (details
not shown). The decline in residual GFR during the study
period was also similar amongst genotype groups.
Patient survival
The patients were followed for 19.4 ± 8.5 months. Dur-
ing the study period, there were 20 deaths. The causes
were myocardial infarction (eight patients), cerebrovas-
cular accident (two patients), peripheral vascular disease
(two patients), peritonitis (two patients), nonperitoni-
tis infections (four patients), suicide (one patient), and
termination of dialysis (one patient). There were 22 trans-
plants, three conversions to hemodialysis, and one recov-
ery of renal function. For patients who remained alive and
on peritoneal dialysis on October 1, 2002, they were ad-
ministratively censored for survival analysis. Survival by
Kaplan-Meier plot showed that patients with CC geno-
type at –2578 position had a significantly better actuar-
ial survival than those with CA/AA genotype (Fig. 2).
Actuarial patient survival was 90.3% and 74.9% at 24
months for CC and CA/AA groups, respectively (P =
0.036). It could be estimated that the unadjusted hazard
ratio of death was 2.87 (95% CI, 1.05 to 7.84) for the
CA/AA group as compared to CC group. Despite a sig-
nificant linkage dysequilibrium between –1154 and –2578
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Fig. 1. The 24-hour dialysate to plasma
(D/P) creatinine by dialysis adequacy and
transport test (DATT) at 0 and 12 months ac-
cording to genotype. (A) At –1154 position.
(B) At –2578 position.
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Fig. 2. Kaplan-Meier survival estimates of patients with CC and
CA/AA genotype at the –2578 position. VEGF is vascular endothe-
lial growth factor.
positions, genetic polymorphism at –1154 position was
not associated patient survival.
As described in the Methods section, we constructed a
multivariable Cox model with two independent covari-
ates: genotype group at –2578 position and a propen-
sity score that incorporated all the potential confounders.
From this model, it could be estimated that after correct-
ing for confounding covariates, the adjusted hazard ratio
of death was 3.04 (95% CI, 1.10 to 8.36, P = 0.032) for
the CA/AA group as compared to CC group.
Correlations between polymorphism, serum VEGF,
and local peritoneal production in vivo
To determine the functional significance of the VEGF
genotypes, we studied VEGF production in vivo in 35
randomly selected patients. Baseline serum VEGF level
was significantly higher in patients with CC genotype than
those with CA/AA genotype at –2578 position (541.5 ±
322.8 pg/mL versus 298.8 ± 209.4 pg/mL, P = 0.012)
(Fig. 3). On the other hand, serum VEGF level was only
marginally higher in patients with GG genotype than
those with GA/AA genotype at –1154 position (449.3 ±
317.4 pg/mL versus 306.1 ± 190.4 pg/mL, P = 0.16), but
the difference was not statistically significant.
In contrast to the serum level, VEGF concentration in
peritoneal dialysis effluent was marginally lower in pa-
tients with CC genotype than those with CA/AA geno-
type at –2578 position (80.6 ± 93.3 pg/mL versus 170.0 ±
199.9 pg/mL, P = 0.12) (Fig. 3). The VEGF mRNA ex-
pression in peritoneal dialysis effluent was significantly
lower in patients with CC genotype than those with
CA/AA genotype at –2578 position (1.82 ± 2.77 ver-
sus 4.48 ± 3.28, P = 0.021) (Fig. 3). Neither the VEGF
concentration nor mRNA expression in PDE differs be-
tween the genotype groups at –1154 position (details not
shown). Serum VEGF level did not correlate with VEGF
concentration in PDE (r =0.04, P =0.8) or VEGF mRNA
expression in PDE (r = −0.08, P = 0.9).
In addition to the effect of genetic polymorphism,
VEGF concentration in peritoneal dialysis effluent signif-
icantly correlated with serum albumin level (r = −0.370,
P = 0.03) and serum CRP level (r = 0.359, P = 0.034).
On the other hand, serum VEGF concentration did not
correlate with either of the inflammatory marker. Nei-
ther the serum albumin nor CRP level differ significantly
among genotype groups (details not shown). Because in
vivo VEGF production was only studied in 35 patients,
the effects of serum or peritoneal dialysis effluent VEGF
level on patient survival and longitudinal change in peri-
toneal transport were not examined.
DISCUSSION
In this series of work, we found that the AA genotype
of VEGF promoter at –2578 position was associated with
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progressive increase in peritoneal transport. When com-
pared to the “wild-type” CC genotype, the CA/AA geno-
type at the –2578 position had lower serum VEGF level
but higher VEGF mRNA gene expression from peri-
toneal dialysis effluent. Furthermore, the CA/AA geno-
type at this position was also associated with a worse
actuarial survival in peritoneal dialysis patients. Although
the polymorphism at –1154 position was also associated
with the change in peritoneal transport with time, only
the polymorphism at –2578 position, but not that at –1154
position, was associated with a difference in VEGF pro-
duction in vivo as well as patient survival. Therefore, we
believe the polymorphism at –2578 position is the pivotal
site for regulation of VEGF secretion. Interestingly, none
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Fig. 3. Comparison of vascular endothelial growth factor (VEGF) pro-
duction in vivo between patients with CC and CA/AA genotype at the
–2578 position. (A) Serum VEGF level. (B) VEGF level in peritoneal
dialysis effluent (PDE). (C) VEGF mRNA expression in PDE.
of the previous studies on VEGF genotype examined the
phenotypic effect of polymorphism at –1154 position. It
should be noted that amongst all the reported polymor-
phism of the VEGF gene, we chose the ones at –1154 and
–2578 positions for study because they were found to have
substantial effect on the serum VEGF level in previous
studies [6, 8]. We did not study the polymorphism at −634
position, which was associated with diabetic retinopathy
[9], because of its effect on serum VEGF level was rela-
tively minor.
In this cohort of new peritoneal dialysis patients, we
found that VEGF genetic polymorphism did not corre-
late with the baseline peritoneal transport characteristics.
On the other hand, VEGF genetic polymorphism had
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significant effect on the longitudinal change of peritoneal
transport after peritoneal dialysis was initiated. Our find-
ings are in keeping with the current understanding in the
pathophysiology of peritoneal dialysis–related peritoneal
microvascular alterations. In essence, conventional
peritoneal dialysis solution that has a high glucose con-
centration can cause vascular alterations within the peri-
toneal membrane by increasing the production of VEGF
[27]. High glucose dialysis solutions increased VEGF
synthesis by peritoneal vascular endothelial cells [28].
Glucose-induced structural and functional microvascular
alterations of peritoneal membrane could be prevented
by treatment with neutralizing anti-VEGF antibody [29].
Human peritoneal mesothelial cells can also secrete
VEGF in response to the high glucose and glucose
degradation product in peritoneal dialysis solution [30].
Continuous exposure of the peritoneal membrane to
glucose-based dialysis solutions is an important stimu-
lus for VEGF expression [31], and dialysate VEGF con-
centrations was associated with high peritoneal solute
transport rate [32]. Taken together, the body of evidence
suggests that VEGF is responsible for the progressive
peritoneal hyperpermeability and fibrosis observed in
long-term peritoneal dialysis patients [30, 31], which
probably explains our observation that VEGF genotype
was associated with the longitudinal change but not the
baseline peritoneal transport characteristics.
If glucose is the major culprit for the progressive peri-
toneal hyperpermeability observed in long-term peri-
toneal dialysis patients, it follows that VEGF genotype
would be associated with the baseline peritoneal trans-
port characteristics of diabetic patients, who have long-
standing endogenous hyperglycemia before the initiation
of dialysis. Although we could not find such an association
in our present study (details not shown), the number of
diabetic subjects examined was relatively small and statis-
tical power may not be adequate. Similarly, although we
found that the longitudinal change in peritoneal transport
characteristics of patients with and without peritonitis
episodes were similarly affected by the VEGF genotype,
our results, which were based on subgroup analysis of
a limited number of patients, did not exclude a possible
interaction between peritonitis and VEGF on progres-
sive peritoneal hyperpermeability and fibrosis. Recent
experiments showed that peritoneal VEGF production is
increased in the presence of proinflammatory cytokines
[31] and lipopolysaccharide [33].
The major shortcoming of our present study was the
use of DATT rather than standard peritoneal equili-
bration test for monitoring of peritoneal transport. Un-
fortunately, because of practical difficulties, standard
peritoneal equilibration test was not repeated in the
present study. The longitudinal change of peritoneal
transport was determined by the serial DATT. It should
be noted that peritoneal equilibration test is carried out
under definite and standardized conditions and is rela-
tively reproducible. On the other hand, DATT varies with
the prescription used by the patient (for example, the
number of exchanges done per day, and the relative du-
rations of the dwells) and the result is potentially less reli-
able. Nevertheless, we have demonstrated in our previous
study that DATT and standard peritoneal equilibration
test had a reasonable agreement in the classification of
peritoneal transport type for Chinese peritoneal dialysis
patients [18]. Rocco, Jordan, and Burkart [14] found that
DATT was useful for monitoring changes in peritoneal
transport over time. To avoid the confounding effect of
dialysis regimen [14], we selected only those peritoneal
dialysis patients with the same dialysis regimen after
12 months of follow-up for serial study.
Another major shortcoming of our study was that we
only studied the change in peritoneal transport in patients
who remained on the same peritoneal dialysis regimen
after 12 months. Although they comprised over 60% of
the recruited patients, the data were likely to be biased
toward stable patients and might not be representative of
the general dialysis population.
Furthermore, the study population of our present study
was limited in size. For example, the AA genotype at both
positions, which was associated with progressive peri-
toneal transport increase, was in each case represented by
a very small number of patients (8 and 9, respectively).
On one hand, it shows that the AA genotype at either
position accounts for the increase in peritoneal transport
in only a small proportion of cases. On the other hand,
it was practically difficult to recruit an adequate num-
ber of cases with the AA genotype for survival analysis.
Since AA genotype was rare and the A allele was the mu-
tant, we put the AA and CA genotypes at –2578 position
(i.e., all cases who had at least one mutant allele) as one
group for survival analysis. Nevertheless, estimation by
the Power Analysis and Sample Size for Windows soft-
ware (PASS 2000, NCSS, Kaysville, UT, USA) shows that
a sample size of 130, or 20 events, achieves 80% statistical
power when the proportions surviving in each group are
0.90 and 0.75 at a significance level (alpha) of 0.05 using
a two-sided log rank test.
We found the VEGF genotype was also an independent
predicting factor of patient mortality. Although serum
VEGF level has been found to predict survival in many
types of cancer [34–36], there was no similar study in non-
malignant diseases. We believe our finding was probably
an indirect effect of VEGF genotype on systemic inflam-
mation and peritoneal transport status. Stompor et al [37]
reported that systemic inflammation in peritoneal dialysis
patients was associated with increased VEGF produc-
tion. In our present study, there was significant correla-
tion between VEGF concentration in peritoneal dialysis
effluent and the levels of serum CRP and albumin. On
the other hand, based on the data of the CANUSA study,
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Churchill et al [38] found that peritoneal dialysis patients
with higher peritoneal transport was associated with in-
creased risk of either technique failure or death. Our pre-
vious study also showed that high peritoneal transporter
was associated with excess short-term patient morbidity
[39]. It is generally believed that high peritoneal trans-
porter causes chronic volume overload and, as a result,
excess cardiovascular disease. Furthermore, VEGF pro-
motes angiogenesis in the setting of tissue ischemia [40]
and possibly has a beneficial effect on heart disease [41].
Unfortunately, our present study does not have adequate
sample size to dissect the effect of VEGF genotype on
cardiovascular mortality.
We found contradicting effect of VEGF promoter poly-
morphism at –2578 position on serum VEGF level and
peritoneal VEGF production in vivo. The “wild-type” CC
genotype at this position was associated with a higher
serum VEGF level than the CA/AA genotype, which
was concordant with the finding of Shahbazi et al [8].
At a glance, it would be reasonable to predict that with a
higher serum VEGF level, the CC genotype would cause
increase in peritoneal transport with time, and possibly a
higher mortality as a result. However, we found that the
CC genotype was actually protective for peritoneal func-
tion and was associated with better actuarial survival. This
paradox was explained by the lower peritoneal VEGF
production by the CC genotype. Although the number
of subject in this part of our study was small and need
further confirmation, we found similar differences in the
mRNA expression in peritoneal dialysis effluent by RT-
QPCR and VEGF level in peritoneal dialysis effluent by
ELISA. Our finding suggests that systemic and local peri-
toneal VEGF production may be differentially regulated.
We hypothesize that the “wild-type” CC genotype is re-
sponsible for a high baseline systemic VEGF production,
but is resistant to the glucose and/or glucose degradation
product induced peritoneal VEGF production, possibly
in the mesothelial cells. Nevertheless, this hypothesize
will have to be tested in another series of experiments
with detailed reporter gene assay.
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